1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Global HER2-Negative Breast Cancer Market 2015-2019

Global HER2-Negative Breast Cancer Market 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 50 pages

About HER2-negative breast cancer
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.

Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.

Based on type of drug molecule, the market is segmented as follows:
- Biologics
- Small molecules
Based on route of administration, the market is segmented as follows:
- Oral
- Parenteral

This report includes a discussion of the market in the following three regions:
- Americas (the US, Canada, Mexico, and Brazil)
- EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
- APAC (Japan, China, Australia, Singapore, South Korea, and India)

Technavio's report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key Vendors
- F. Hoffmann-La Roche
- Novartis
- Pfizer

Other prominent vendors
- AbbVie
- AstraZeneca
- BioMarin
- Bristol-Myers Squibb
- Eisai
- Eli Lilly
- Galena Biopharma
- Incyte
- Merck
- Merck Serono
- Merrimack
- Nektar
- Tesaro

Key market driver
- Significant unmet needs
- For a full, detailed list, view our report

Key market challenge
- Premium-priced therapies
- For a full, detailed list, view our report

Key market trend
- Emerging therapies
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global HER2-Negative Breast Cancer Market 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by type of drug molecule
Biologics
Small molecules
PART 07: Market segmentation by route of administration
Oral
Parenteral
PART 08: Geographical segmentation
Market segmentation by geography 2014-2019
HER2-negative breast cancer market in Americas 2014-2019
HER2-negative breast cancer market in EMEA 2014-2019
HER2-negative breast cancer market in APAC 2014-2019
PART 09: Pipeline portfolio
Key information about late-stage pipeline candidates
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis
Other and future prominent vendors
PART 16: Key vendor analysis
F. Hoffmann-La Roche
Novartis
Pfizer
PART 17: Appendix
List of abbreviations
PART 18: EExplore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global HER2-negative breast cancer market 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Segmentation of global HER2-negative breast cancer market by geography 2014
Exhibit 05: HER2-negative breast cancer market in Americas 2014-2019 ($ millions)
Exhibit 06: HER2-negative breast cancer market in EMEA 2014-2019 ($ millions)
Exhibit 07: HER2-negative breast cancer market in APAC 2014-2019 ($ millions)
Exhibit 08: Region-wise comparison of market size 2014-2019 ($ millions)
Exhibit 09: Major pipeline drug candidates in phase III stage of development
Exhibit 10: Impact of drivers
Exhibit 11: Impact of drivers and challenges
Exhibit 12: Vendor ranking 2014
Exhibit 13: Key takeaways: F. Hoffmann-La Roche
Exhibit 14: Novartis: Sales and YoY growth of Afinitor 2012-2014 ($ millions)
Exhibit 15: Key takeaways: Novartis
Exhibit 16: Key takeaways: Pfizer
Exhibit 17: Business segmentation 2013 and 2014 by revenue ($ billions)
Exhibit 18: Geographical segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Breast Cancer: Analytical Tool

Breast Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Europe - Forecast

  • December 2016
  • Cancer  

  • Europe  

    World  

View report >

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Breast Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.